On September 26, 2021, Bluebell Capital Partners announced that it is due to meet Sir Jonathan Symonds GlaxoSmithKline’s chairman within weeks. Bluebell stated that it wants GlaxoSmithKline chief executive Emma Walmsley to reapply for her job ahead of the separation of the group's biopharma and consumer businesses next year. Bluebell also wants a proactive' approach to considering a sale rather than a demerger of the consumer arm.